167 related articles for article (PubMed ID: 38601689)
21. [Investigation of Humoral and Cellular Immunity in TOBB ETÜ Hospital Workers After Three Doses of CoronaVac Vaccination and after One Dose of Comirnaty Vaccination Following Two Doses of CoronaVac].
Özyurda F; Ardıçoğlu Akışın Y; Mert T; Poyraz B; Özkan Y; Turan M; Göçmen JS; Yücel A; Akar N
Mikrobiyol Bul; 2022 Jul; 56(3):387-403. PubMed ID: 35960233
[TBL] [Abstract][Full Text] [Related]
22. Exploring the vaccine-induced immunity against severe acute respiratory syndrome coronavirus 2 in healthcare workers.
Lim YK; Kweon OJ; Choi Y; Yoon S; Kim TH; Lee MK
Sci Rep; 2023 Apr; 13(1):6830. PubMed ID: 37100845
[TBL] [Abstract][Full Text] [Related]
23. Cellular and humoral immune responses and breakthrough infections after three SARS-CoV-2 mRNA vaccine doses.
Almendro-Vázquez P; Chivite-Lacaba M; Utrero-Rico A; González-Cuadrado C; Laguna-Goya R; Moreno-Batanero M; Sánchez-Paz L; Luczkowiak J; Labiod N; Folgueira MD; Delgado R; Paz-Artal E
Front Immunol; 2022; 13():981350. PubMed ID: 36059485
[TBL] [Abstract][Full Text] [Related]
24. Assessment of humoral and cellular immunity induced by the BNT162b2 SARS-CoV-2 vaccine in healthcare workers, elderly people, and immunosuppressed patients with autoimmune disease.
Malipiero G; Moratto A; Infantino M; D'Agaro P; Piscianz E; Manfredi M; Grossi V; Benvenuti E; Bulgaresi M; Benucci M; Villalta D
Immunol Res; 2021 Dec; 69(6):576-583. PubMed ID: 34417958
[TBL] [Abstract][Full Text] [Related]
25. Long-term humoral and cellular immunity after primary SARS-CoV-2 infection: a 20-month longitudinal study.
Hvidt AK; Guo H; Andersen R; Lende SSF; Vibholm LK; Søgaard OS; Schleimann MH; Russell V; Cheung AM; Paramithiotis E; Olesen R; Tolstrup M
BMC Immunol; 2023 Nov; 24(1):45. PubMed ID: 37974069
[TBL] [Abstract][Full Text] [Related]
26. Humoral and cellular responses to repeated COVID-19 exposure in multiple sclerosis patients receiving B-cell depleting therapies: a single-center, one-year, prospective study.
Alfonso-Dunn R; Lin J; Lei J; Liu J; Roche M; De Oliveira A; Raisingani A; Kumar A; Kirschner V; Feuer G; Malin M; Sadiq SA
Front Immunol; 2023; 14():1194671. PubMed ID: 37449202
[TBL] [Abstract][Full Text] [Related]
27. Antibody levels following vaccination against SARS-CoV-2: associations with post-vaccination infection and risk factors in two UK longitudinal studies.
Cheetham NJ; Kibble M; Wong A; Silverwood RJ; Knuppel A; Williams DM; Hamilton OKL; Lee PH; Bridger Staatz C; Di Gessa G; Zhu J; Katikireddi SV; Ploubidis GB; Thompson EJ; Bowyer RCE; Zhang X; Abbasian G; Garcia MP; Hart D; Seow J; Graham C; Kouphou N; Acors S; Malim MH; Mitchell RE; Northstone K; Major-Smith D; Matthews S; Breeze T; Crawford M; Molloy L; Kwong ASF; Doores K; Chaturvedi N; Duncan EL; Timpson NJ; Steves CJ
Elife; 2023 Jan; 12():. PubMed ID: 36692910
[TBL] [Abstract][Full Text] [Related]
28. Humoral and Cellular Immune Responses to Vector, Mix-and-Match, or mRNA Vaccines against SARS-CoV-2 and the Relationship between the Two Immune Responses.
Nam M; Yun SG; Kim SW; Kim CG; Cha JH; Lee C; Kang S; Park SG; Kim SB; Lee KB; Chung YS; Nam MH; Lee CK; Cho Y
Microbiol Spectr; 2022 Aug; 10(4):e0249521. PubMed ID: 35946811
[TBL] [Abstract][Full Text] [Related]
29. Long-Term SARS-CoV-2-Specific Humoral and T Cell Responses after the BNT162b2 or BBIBP-CorV Booster and the Incidence of Breakthrough Infections among Healthcare Workers.
Matula Z; Bekő G; Király V; Gönczi M; Zóka A; Baráth A; Uher F; Vályi-Nagy I
Vaccines (Basel); 2023 Dec; 12(1):. PubMed ID: 38276662
[TBL] [Abstract][Full Text] [Related]
30. Induction of High Levels of Specific Humoral and Cellular Responses to SARS-CoV-2 After the Administration of Covid-19 mRNA Vaccines Requires Several Days.
Gil-Manso S; Carbonell D; López-Fernández L; Miguens I; Alonso R; Buño I; Muñoz P; Ochando J; Pion M; Correa-Rocha R
Front Immunol; 2021; 12():726960. PubMed ID: 34671348
[TBL] [Abstract][Full Text] [Related]
31. Longitudinal Follow-Up of the Immunity to SARS-CoV-2 in Health Care Workers in Argentina: Persistence of Humoral Response and Neutralizing Capacity after Sputnik V Vaccination.
Castro EF; Acosta J; Moriena L; Rios Medrano M; Tejerina Cibello M; Codino E; Taborda MÁ; Álvarez DE; Cavatorta AL
mSphere; 2023 Jun; 8(3):e0066222. PubMed ID: 37070983
[TBL] [Abstract][Full Text] [Related]
32. Differential vaccine-induced kinetics of humoral and cellular immune responses in SARS-CoV-2 naive and convalescent health care workers.
Smit W; Thijsen S; van der Kieft R; van Tol S; Reimerink J; Reusken C; Rümke L; Bossink A; Limonard G; Heron M
Pathog Dis; 2022 Oct; 80(1):. PubMed ID: 36089571
[TBL] [Abstract][Full Text] [Related]
33. Cellular and humoral responses after second and third SARS-CoV-2 vaccinations in patients with autoimmune diseases treated with rituximab: specific T cell immunity remains longer and plays a protective role against SARS-CoV-2 reinfections.
Egri N; Calderón H; Martinez R; Vazquez M; Gómez-Caverzaschi V; Pascal M; Araújo O; Juan M; González-Navarro EA; Hernández-Rodríguez J
Front Immunol; 2023; 14():1146841. PubMed ID: 37180097
[TBL] [Abstract][Full Text] [Related]
34. An Immune Response to Heterologous ChAdOx1/BNT162b2 Vaccination against COVID-19: Evaluation of the anti-RBD Specific IgG Antibodies Titers and Interferon Gamma Release Assay (IGRA) Test Results.
Zalewska M; Fus W; Konka A; Wystyrk K; Bochenek A; Botor H; Fronczek M; Zembala-John J; Adamek B
Vaccines (Basel); 2022 Sep; 10(9):. PubMed ID: 36146624
[TBL] [Abstract][Full Text] [Related]
35. Cluster Analysis Identifies Distinct Patterns of T-Cell and Humoral Immune Responses Evolution Following a Third Dose of SARS-CoV-2 Vaccine in People Living with HIV.
El Moussaoui M; Desmecht S; Lambert N; Maes N; Braghini J; Marechal N; Quintana C; Briquet K; Gofflot S; Toussaint F; Hayette MP; Vermeersch P; Lutteri L; Grégoire C; Beguin Y; Rahmouni S; Moutschen M; Desmecht D; Darcis G
Viruses; 2023 Jun; 15(7):. PubMed ID: 37515123
[TBL] [Abstract][Full Text] [Related]
36. Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label study.
Moor MB; Suter-Riniker F; Horn MP; Aeberli D; Amsler J; Möller B; Njue LM; Medri C; Angelillo-Scherrer A; Borradori L; Radonjic-Hoesli S; Seyed Jafari SM; Chan A; Hoepner R; Bacher VU; Mani LY; Iype JM; Hirzel C; Maurer B; Sidler D
Lancet Rheumatol; 2021 Nov; 3(11):e789-e797. PubMed ID: 34514436
[TBL] [Abstract][Full Text] [Related]
37. High vaccination coverage and infection rate result in a robust SARS-CoV-2-specific immunity in the majority of liver cirrhosis and transplant patients: A single-center cross-sectional study.
von der Schulenburg P; Herting A; Harberts A; Lütgehetmann M; Jahnke-Triankowski J; Pischke S; Piecha F; Drolz A; Jörg V; Hübener P; Wehmeyer M; Addo MM; Fischer L; Lohse AW; Schulze Zur Wiesch J; Sterneck M
United European Gastroenterol J; 2024 Apr; 12(3):339-351. PubMed ID: 38279837
[TBL] [Abstract][Full Text] [Related]
38. Persistence of Immune Response in Health Care Workers After Two Doses BNT162b2 in a Longitudinal Observational Study.
Herzberg J; Fischer B; Lindenkamp C; Becher H; Becker AK; Honarpisheh H; Guraya SY; Strate T; Knabbe C
Front Immunol; 2022; 13():839922. PubMed ID: 35309303
[TBL] [Abstract][Full Text] [Related]
39. Humoral and Cellular Responses to BNT162b2 as a Booster Following Two Doses of ChAdOx1 nCov-19 Determined Using Three SARS-CoV-2 Antibody Assays and an Interferon-Gamma Release Assay: A Prospective Longitudinal Study in Healthcare Workers.
Jeong S; Lee N; Lee SK; Cho EJ; Hyun J; Park MJ; Song W; Kim HS
Front Immunol; 2022; 13():859019. PubMed ID: 35720318
[TBL] [Abstract][Full Text] [Related]
40. Kinetics and persistence of cellular and humoral immune responses to SARS-CoV-2 vaccine in healthcare workers with or without prior COVID-19.
Chivu-Economescu M; Bleotu C; Grancea C; Chiriac D; Botezatu A; Iancu IV; Pitica I; Necula LG; Neagu A; Matei L; Dragu D; Sultana C; Radu EL; Nastasie A; Voicu O; Ataman M; Nedeianu S; Mambet C; Diaconu CC; Ruta SM
J Cell Mol Med; 2022 Feb; 26(4):1293-1305. PubMed ID: 35043552
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]